También han lanzado rumores de buyout, con el indiscutible argumento de que antes de un buyout suele haber una reestructuración de plantilla. Con esas razones de peso era de esperar que la subida fuera flor de un día. Sigo pensando que habrá que esperar al desarrollo de los gen2 o a que venda algo en Europa de una vez por todas. :-(
No la sigo. Te lo colgaba porque me he topado con ello por casualidad y porque lo habías comentado.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Bueno, a estas horas, pre de AGEN +10%.....
A ver si no sale rana como ayer con las ONTY, y pega una buena subida....
Un saludo y suerte....
Threshold Pharmaceuticals Announces New Data on TH-302 to Be Presented at AACR-NCI-EORTC
Early Clinical Data on Combinations of TH-302 With Anti-Angiogenic Therapies in Solid Tumors; Preclinical Data on Combinations of TH-302 With Gemcitabine and Nab-Paclitaxel in Models of Pancreatic Cancer
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data on its investigational hypoxia-targeted drug, TH-302, will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19 - 23, 2013, in Boston, MA. The presentations will characterize early data from two ongoing clinical trials evaluating combinations of TH-302 with anti-angiogenic agents in solid tumors as well as preclinical data on the tolerability and activity of TH-302, gemcitabine, and nab-paclitaxel combinations in models of pancreatic cancer.
New data from a Phase 1 clinical trial combining TH-302 and pazopanib (Investigator Sponsored Trial 4001) in patients with advanced solid tumors will be presented in a poster session on Tuesday, October 22 (Abstract #C61). Updated data from a Phase 1/2 clinical trial combining TH-302 and sunitinib (Study 410) in patients with renal cell carcinoma, gastrointestinal tumors, or pancreatic neuroendocrine tumors will be presented in a poster session on Monday, October 21 (Abstract #B77). Emerging preclinical research suggests that anti-angiogenic therapy may increase tumor hypoxia. These two clinical trials further characterize the potential of combining TH-302 with anti-angiogenic agents.
In addition, results from preclinical research evaluating combinations of TH-302, gemcitabine, and nab-paclitaxel in xenograft models of pancreatic cancer will be presented in a poster session on Tuesday, October 22 (Abstract #C287).
Abstracts are now available on the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Online Proceedings and Itinerary Planner Web page, which can be accessed at http://www.abstractsonline.com/plan/start.aspx?mkey=%7B18FA2242%2DFD0D%2D4689%2D82A0%2DE4D68AC8A74A%7D.
Pues no la sigas mucho que con que la sufra yo ya hay suficiente para los dos.
DCTH
A ver si tiene otro repunte como el de ayer y me las quito de encima ahora que puedo sacarles algo...q miedo me da pensar que la subida es por despedir a la gente y no por resultados futuros...
DCTH
